Vigilant Biosciences’ innovative BeVigilant™ RAPID Test is based on patented technology that detects specific protein markers clinically shown to be associated with early stage cancers, potentially even prior to visual or physical indicators. The BeVigilant RAPID Test is CE Marked and available in select markets outside the United States.